noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

State of Oregon

New deadline to claim food loss due to Flat Fire in two counties
Elizabeth Warren

Warren, Hirono Lead Senate Armed Services Committee Democrats in[...]
Mineralys Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Healthcare

Lyell Immunopharma Inc.

09/16/2025 | Press release | Distributed by Public on 09/16/2025 14:23

Management Change/Compensation (Form 8-K)

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 15, 2025, Charles Newton notified Lyell Immunopharma, Inc. (the "Company") of his decision to resign from his position as the Chief Financial Officer and principal financial and accounting officer of the Company, effective October 31, 2025 (the "Resignation Date"). There were no disagreements between Mr. Newton and the Company. The Company plans to conduct a search for Mr. Newton's replacement. The Company and Mr. Newton have entered into a consulting agreement under which Mr. Newton may provide consulting services to the Company following the Resignation Date until April 30, 2026 or any earlier termination of the consultancy by either party.

Lyell Immunopharma Inc. published this content on September 16, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 16, 2025 at 20:23 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]